Non tuberculous mycobacterial infections;Les infections à mycobactéries non tuberculeuses

Revue de Medecine Interne

Volumn 29, Issue 5, 2008, Pages 370-379

  Prendki, V ^a   Germaud, P ^b   Bemer, P ^c   Masseau, A ^c   Hamidou, M ^c  

^a AVICENNE HOSPITAL   (France)

^b CHU de Nantes   (France)

^c HÔTEL DIEU   (France)

Author keywords

Atypical mycobacteria; Disseminated infections; Immunological deficiency; Pulmonary infections; Susceptibility genes

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; DOXYCYCLINE FOSFATEX; ETHAMBUTOL; GAMMA INTERFERON; IMIPENEM; ISONIAZID; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; PYRIDOXINE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE;

ATYPICAL MYCOBACTERIOSIS; BURULI ULCER; COMBINATION CHEMOTHERAPY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; LUNG INFECTION; LUNG LAVAGE; MYCOBACTERIUM; OSTEOARTHROPATHY; PATHOGENESIS; PREVALENCE; SHORT SURVEY; SKIN INFECTION; TREATMENT FAILURE;

AGED; FRANCE; HUMANS; IMMUNOSUPPRESSION; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM INFECTIONS, ATYPICAL; PREVALENCE;

EID: 43049112044     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.09.030     Document Type: Short Survey

References (60)

1. American Thoracic Society., Wallace Jr. R.J., Glassroth J., et al. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 156 (1997) S1-S25
2. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. ATS Mycobacterial Diseases Subcommittee. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 (2007) 367-416
3. Wayne L.G., and Sramek H.A. Agents of newly recognized or infrequently encountered mycobacterial diseases. Clin Microbiol Rev 5 (1992) 1-25
4. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 16 (2003) 319-354
5. Astagneau P., Desplaces N., Vincent V., Chicheportiche V., Botherel A., Maugat S., et al. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet 358 (2001) 747-751
6. Dailloux M., Albert M., Laurain C., Andolfatto S., Lozniewski A., Hartemann P., et al. Mycobacterium xenopi and drinking water biofilms. Appl Environ Microbiol 69 (2003) 6946-6948
7. Casanova J.L. Mendelian predisposition to mycobacterial infections in humans. J Soc Biol 194 (2000) 25-28
8. Holland S.M., Eisenstein E.M., Kuhns D.B., Turner M.L., Fleisher T.A., Strober W., et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 330 (1994) 1348-1355
9. Hallstrand T.S., Ochs H.D., Zhu Q., and Liles W.C. Inhaled IFN-gamma for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-gamma deficiency. Eur Respir J. 24 (2004) 367-370
10. Huang H., Kao P., Adi V., and Ruoss S. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without pre-existing lung disease: diagnosis and management limitations. Chest 115 (1999) 1033-1040
11. Dailloux M., Abalain M.L., Laurain C., Lebrun L., Loos-Ayav C., Lozniewski A., et al. French Mycobacteria Study Group. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J 28 (2006 Dec) 1211-1215
12. Andréjak C., Lescure F.X., Douadi Y., Laurans G., Smail A., Duhaut P., et al. Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. Infect 55 (2007) 34-40
13. Marras T.K., and Daley C.L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 23 (2002) 553-567
14. Field S.K., and Cowie R.L. Lung disease due to the more common nontuberculous mycobacteria. Chest 129 (2006) 1653-1672
15. Olivier K., Weber D., Wallace R., Faiz A., Lee J., Zhang Y., et al. Nontuberculous mycobacteria: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 167 (2003) 828-834
16. Wickremasinghe M., Ozerovitch L.J., Davies G., Wodehouse T., Chadwick M.V., Abdallah S., et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 60 (2005) 1045-1051
17. Wallace Jr. R.J., O'Brein R., Glassroth J., Raleigh J., and Dutta A. Diagnosis and treatment of disease caused by non tuberculous mycobacteria. Am Rev Respir Dis 142 (1990) 940-953
18. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
19. Embil J., Warren P., Yakrus M., Stark R., Corne S., Forrest D., et al. Pulmonary illness associated with exposure to Mycobacterium avium complex in hot tub water. Hypersensitivity pneumonitis or infection?. Chest 11 (1997) 813-816
20. Hanak V., Kalra S., Aksamit T.R., Hartman T.E., Tazelaar H.D., and Ryu J.H. Hot tub lung: presenting features and clinical course of 21 patients. Respir Med 100 (2006) 610-615
21. Reich J.M., and Johnson R.E. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere Syndrome. Chest 101 (1992) 1605-1609
22. Prince D.S., Peterson D.D., Steiner R.M., et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321 (1989) 863-868
23. Ellis S.M., and Hansell D.M. Imaging of non tuberculous (atypical) mycobacterial pulmonary infection. Clin Radiol 57 (2002) 661-669
24. Christensen E.E., Dietz G.W., Ahn C.H., Chapman J.S., Murry R.C., Anderson J., et al. Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M kansasii, and M intracellulare infections. Chest 80 (1981) 132-136
25. Lai K., and Stottmeier K.D. Mycobacterial cervical lymphadenopathy. JAMA 251 (1984) 1286-1288
26. Chetchotisakd P., Kiertiburanakul S., Mootsikapun P., Assanasen S., Chaiwarith R., and Anunnatsiri S. Disseminated nontuberculous mycobacterial infection in patients who are not infected with HIV in Thailand. Clin Infect Dis 45 (2007) 421-427
27. Lindeboom J.A., Prins J.M., Bruijnesteijn van Coppenraet E.S., Lindeboom R., and Kuijper E.J. Cervicofacial lymphadenitis in children caused by Mycobacterium haemophilum. Clin Infect Dis 41 (2005) 1569-1575
28. Dodiuk-Gad R., Dyachenko P., Ziv M., Shani-Adir A., Oren Y., Mendelovici S., et al. Nontuberculous mycobacterial infections of the skin: A retrospective study of 25 cases. J Am Acad Dermatol 57 (2007) 413-420
29. Aubry A., Chosidow O., Caumes E., Robert J., and Cambau E. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 162 (2002) 1746-1752
30. Wansbrough-Jones M., and Phillips R. Buruli ulcer: emerging from obscurity. Lancet 367 (2006) 1849-1858
31. Telgt D.S., van den Hoogen F.H., Meis J.F., Lemmens J.A., and van de Putte L.B. Arthritis and spondylodiscitis caused by Mycobacterium xenopi in a patient with systemic lupus erythematosus. Br J Rheumatol 36 (1997) 1025-1026
32. Bernard L., Vincent V., Lortholary O., Raskine L., Vettier C., Colaitis D., et al. Mycobacterium kansasii septic arthritis: French retrospective study of 5 years and review. Clin Infect Dis 29 (1999) 1455-1460
33. Ziza, Jean-Marc, Desplaces, and Nicole. Infections ostéoarticulaires à mycobactéries atypiques. Revue du rhumatisme (2006) 394-400
34. Ingram C., Tanner D., Durack D., Kernodle G., and Corey G. Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis 16 (1993) 463-471
35. Horsburgh C.R. Mycobacterium avium complex in acquired immunodeficiency syndrome. N Engl J Med 324 (1993) 1332-1338
36. Hocqueloux L., Lesprit P., Herrmann J.L., de la Blanchardiere A., Zagdanski A.M., Decazes J.M., et al. Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. Chest 113 (1998) 542-548
37. Nightingale S.D., Byrd L.T., Southern P.M., Jockusch J.D., Cal S.X., and Wynne B.A. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 165 (1992) 1082-1085
38. Marras T.K., and Daley C.L. A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection. J Acquir Immune Defic Syndr 36 (2004) 883-889
39. Corbett E.L., Churchyard G.J., Clayton T., Herselman P., Williams B., Hayes R., et al. Risk factors for pulmonary mycobacterial disease in South African gold miners. A case-control study. Am J Respir Crit Care Med 159 (1999) 94-99
40. Huebner R.E., Schein M.F., and Bass Jr. J.B. The tuberculin skin test. Clin Infect Dis 17 (1993) 968-975
41. Herrmann J.-L., Simonney N., and Lagrange P.-H. Advantages and drawbacks of in vitro Interferon-γ/T cell assays compared to the Mantoux test for the diagnosis of tuberculosis. Arch Pediatr 14 (2007 Feb) 207-211
42. Rastogi N., Frehel C., Ryter A., Ohayon H., Lesourd M., and David H.L. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents. Antimicrob Agents Chemother 20 (1981) 666-677
43. Dautzenberg B., Piperno D., Diot P., Truffot-Pernot C., Chauvin J.P., and The clarithromycin French study group. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 107 (1995) 1035-1040
44. Fernandes P.B., Hardy D.J., McDaniel D., Hanson C.W., and Swanson R.N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 33 (1989) 1531-1534
45. Dautzenberg B. Treatment of non-tuberculous mycobacterial infections. Rev Mal Respir 13 (1996) 81-83
46. Griffith D.E., Brown B.A., Cegielski P., Murphy D.T., and Wallace Jr. R.J. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 30 (2000) 288-292
47. Peloquin C.A., Berning S.E., Nitta A.T., Simone P.M., Goble M., Huitt G.A., et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 38 (2004) 1538-1544
48. Griffith D.E., Brown-Elliott B.A., Langsjoen B., Zhang Y., Pan X., Girard W., et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 174 (2006) 928-934
49. Field K., Fisher D., and Cowie L. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 126 (2004) 566-581
50. Shiraishi Y., Nakajima Y., Takasuna K., Hanaoka T., Katsuragi N., and Konno H. Surgery for MAC lung disease in the clarithromycin era. Eur J Car 21 (2002) 314-318
51. Dautzenberg B et le groupe d'étude et de traitement des infections à mycobactéries résistantes (GETIM). Traitement des infections pulmonaires à mycobactéries atypiques chez les malades séro-négatifs pour le VIH. Document GETIM, janvier 1996.
52. Lindeboom J.A., Kuijper E.J., Bruijnesteijn van Coppenraet E.S., Lindeboom R., and Prins J.M. Surgical excision versus antibiotic treatment for nontuberculous mycobacterialcervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 44 (2007) 1057-1064
53. Wallace Jr. R.J., Swenson J.M., Silcox V.A., and Bullen M.G. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 152 (1985) 500-514
54. Bermudez L.E., Kolonoski P., Petrofsky M., Wu M., Inderlied C.B., and Young L.S. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis 187 (2003) 1977-1980
55. Alcaide F., Calatayud L., Santin M., and Martin R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 48 (2004) 4562-4565
56. Wallace Jr. R.J., Brown-Elliott B.A., Crist C.J., Mann L., and Wilson R.W. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 46 (2002) 3164-3167
57. Daley C.L., and Griffith D.E. Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med 23 (2002) 623-632
58. Holland S.M. Immunotherapy of mycobacterial infections. Semin Respir Infect 16 (2001) 47-59
59. Jenkins P.A., and Campbell I.A. Research Committee of The British Thoracic Society. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. Respir Med 97 (2003) 439-444
60. Safdar A., White D.A., Stover D., Armstrong D., and Murray H.W. Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med 113 (2002) 756-759